Table 3.
Demographic and clinical characteristics at week 24 among participants who underwent vitamin D3 supplementation
| WNon-responders | Responders | P-value | |
|---|---|---|---|
| (25(OH)D < 30 ng/mL) | (25(OH)D ≥30 ng/mL) | ||
| (n = 8) | (n = 52) | ||
| 25(OH)D (ng/mL)a | 26 (25, 27) | 47 (40, 65) | <0.001 |
| Male sex | 63 % (5) | 65 % (34) | 1.00 |
| Age (years) | 42 (36, 48) | 48 (39, 54) | 0.27 |
| White race/ethnicity | 63 % (5) | 54 % (28) | 0.72 |
| Baseline CD4+ T lymphocyte (cells/mm3) | 540 (509, 758) | 689 (527, 833) | 0.69 |
| ≥500 | 71 % (5) | 77 % (37) | |
| 350–499 | 14 % (1) | 17 % (8) | |
| <350 | 14 % (1) | 6 % (3) | |
| Week 24 CD4+ T lymphocyte (cells/mm3) | 656 (600, 891) | 712 (460, 853) | 0.50 |
| ≥500 | 100 % (5) | 67 % (22) | |
| 350–499 | 0 (0) | 21 % (7) | |
| <350 | 0 (0) | 12 % (4) | |
| Time on cART (years) | 5 (4, 8) | 5 (5, 6) | 0.96 |
| Time on TDF (years) | 4 (3, 5) | 3 (0, 5) | 0.30 |
| Time on AZT (years) | 0 (0, 2) | 1 (0, 5) | 0.50 |
| Time on EFV (years) | 2 (2, 4) | 4 (3, 5) | 0.31 |
| Time on PI (years) | 1 (0, 6) | 0 (0, 2) | 0.36 |
| Current TDF use | 100 % (8) | 65 % (34) | 0.09 |
| Current AZT use | 0 % (0) | 39 % (20) | 0.04 |
| Current EFV use | 50 % (4) | 79 % (41) | 0.10 |
| Current PI use | 38 % (3) | 19 % (10) | 0.35 |
| Baseline BMIb (kg/m2) | 23 (23, 24) | 25 (24, 28) | 0.23 |
| <18.5 | 0 % (0) | 0 % (0) | |
| 18.5–24.9 | 100 % (3) | 48 % (15) | |
| 25.0–29.9 | 0 % (0) | 32 % (10) | |
| ≥30.0 | 0 % (0) | 19 % (6) | |
| C-reactive protein (mg/dL) | 0.3 (0.2, 0.4) | 0.3 (0.2, 0.9) | 0.36 |
| Glucose (mg/dL) | 82 (80, 89) | 91 (87, 103) | 0.02 |
| HbA1c (%) | 5.5 (5.5, 5.8) | 5.5 (5.2, 5.8) | 0.62 |
| Triglycerides (mg/dL) | 111 (105, 128) | 150 (107, 201) | 0.12 |
| Total cholesterol (mg/dL) | 187 (166, 200) | 198 (173, 225) | 0.41 |
| HDL (mg/dL) | 51 (48, 53) | 47 (40, 60) | 0.52 |
| LDL (mg/dL) | 111 (94, 124) | 110 (93, 133) | 0.87 |
Median (interquartile range) or percent (n) presented
25(OH)D 25-hydroxyvitamin D, TDF tenofovir, AZT zidovudine, EFV efavirenz, PI protease inhibitors, BMI body mass index, HbA1c glycated hemoglobin
aNo available 25(OH)D at week 24 for 3 participants
bData available for 54 patients (19 in sufficiency group, 35 in deficiency group)